当前位置: 首页 >> 检索结果
101. Analysis of the PARAGON-HF Study Results Using Win Ratio.
作者: Minjae Yoon.;Wonse Kim.;Woong Kook.;Jin Joo Park.;Barry Greenberg.
来源: Circ Heart Fail. 2024年17卷9期e011860页
The PARAGON-HF study (Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction) investigated the effect of sacubitril-valsartan in heart failure (HF) with preserved ejection fraction. The results, which were analyzed using conventional statistical methods, did not find a significant reduction in the primary composite end point of cardiovascular death and total hospitalization for HF. Recent clinical trials used win ratio statistics that enable the incorporation of multiple outcome aspects into the primary end point and can detect positive outcomes with fewer patients. In this study, we assessed the effect of sacubitril-valsartan on outcomes using the win ratio to analyze results from patients included in the PARAGON-HF study.
102. Serum Chloride and the Response to Acetazolamide in Patients With Acute Heart Failure and Volume Overload: A Post Hoc Analysis From the ADVOR Trial.
作者: Jef Van den Eynde.;Pieter Martens.;Jeroen Dauw.;Petra Nijst.;Evelyne Meekers.;Jozine M Ter Maaten.;Kevin Damman.;Gerasimos Filippatos.;Johan Lassus.;Alexandre Mebazaa.;Frank Ruschitzka.;Matthias Dupont.;Wilfried Mullens.;Frederik H Verbrugge.
来源: Circ Heart Fail. 2024年17卷10期e011749页
Chloride plays a crucial role in renal salt sensing. This study investigates whether serum chloride is associated with clinical outcomes and decongestive response to acetazolamide in patients with acute decompensated heart failure.
103. Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial.
作者: Miao Yu.;Yong Yang.;Si-Lai Dong.;Chen Zhao.;Fen Yang.;Yuan-Fan Yuan.;Yu-Hua Liao.;Shao-Lin He.;Kun Liu.;Fen Wei.;Hai-Bo Jia.;Bo Yu.;Xiang Cheng.
来源: Circulation. 2024年150卷13期981-993页
Colchicine has been approved to reduce cardiovascular risk in patients with coronary heart disease on the basis of its potential benefits demonstrated in the COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low-Dose Colchicine 2) studies. Nevertheless, there are limited data available about the specific impact of colchicine on coronary plaques.
104. Effects of Sedentary Behavior Reduction on Blood Pressure in Desk Workers: Results From the RESET-BP Randomized Clinical Trial.
作者: Bethany Barone Gibbs.;Subashan Perera.;Kimberly A Huber.;Joshua L Paley.;Molly B Conroy.;John M Jakicic.;Matthew F Muldoon.
来源: Circulation. 2024年150卷18期1416-1427页
Sedentary behavior (SB) is observationally associated with cardiovascular disease risk. However, randomized clinical trials testing causation are limited. We hypothesized that reducing SB would decrease blood pressure (BP) and pulse wave velocity (PWV) in sedentary adults.
105. Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
作者: Nigopan Gopalasingam.;Kristoffer Berg-Hansen.;Kristian Hylleberg Christensen.;Bertil T Ladefoged.;Steen Hvitfeldt Poulsen.;Mads Jønsson Andersen.;Barry A Borlaug.;Roni Nielsen.;Niels Møller.;Henrik Wiggers.
来源: Circulation. 2024年150卷20期1570-1583页
Heart failure with preserved ejection fraction (HFpEF) is a major cause of morbidity and mortality in patients with type 2 diabetes (T2D). Acute increases in circulating levels of ketone body 3-hydroxybutyrate have beneficial acute hemodynamic effects in patients without T2D with chronic heart failure with reduced ejection fraction. However, the cardiovascular effects of prolonged oral ketone ester (KE) treatment in patients with T2D and HFpEF remain unknown.
106. Long Term Outcomes After Renal Revascularization for Atherosclerotic Renovascular Disease in the ASTRAL Trial.
作者: Hannah O'Keeffe.;Darren Green.;Aine de Bhailis.;Rajkumar Chinnadurai.;Keith Wheatley.;Jonathan Moss.;Philip A Kalra.; .
来源: Circ Cardiovasc Interv. 2024年17卷9期e013979页
The ASTRAL trial (Angioplasty and Stenting for Renal Artery Lesions) recruited 806 patients between 2000 and 2007. Patients with atherosclerotic renal artery stenosis (RAS) and clinician uncertainty about the benefit of revascularization were randomized 1:1 to medical therapy with or without renal artery stenting. The initial results were presented in 2009 at a median 33.6-month follow-up, with no benefit of revascularization on renal or cardiovascular outcomes. Surviving patients remained under follow-up until the end of 2013, and the long-term results are presented in this study.
107. Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment-Elevation Myocardial Infarction (STEMI).
作者: Antonio Abbate.;Benjamin Van Tassell.;Vlad Bogin.;Roshanak Markley.;Dmitry V Pevzner.;Paul C Cremer.;Imad Meray.;Dmitry V Privalov.;Angela Taylor.;Sergey A Grishin.;Alina N Egorova.;Ekaterina G Ponomar.;Yan Lavrovsky.;Mikhail Yu Samsonov.; .
来源: Circulation. 2024年150卷7期580-582页 108. Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial.
作者: Sanjay Rajagopalan.;Mirela Dobre.;Jean-Eudes Dazard.;Armando Vergara-Martel.;Kim Connelly.;Michael E Farkouh.;Juan Gaztanaga.;Heather Conger.;Ann Dever.;Laleh Razavi-Nematollahi.;Anas Fares.;Gabriel Pereira.;Jonnelle Edwards-Glenn.;Mark Cameron.;Cheryl Cameron.;Sadeer Al-Kindi.;Robert D Brook.;Bertram Pitt.;Matthew Weir.
来源: Circulation. 2024年150卷9期663-676页
Persistent mineralocorticoid receptor activation is a pathologic response in type 2 diabetes and chronic kidney disease. Whereas mineralocorticoid receptor antagonists are beneficial in reducing cardiovascular complications, direct mechanistic pathways for these effects in humans are lacking.
109. Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial.
作者: Atsushi Tada.;Daniel Burkhoff.;Jwan A Naser.;Tomonari Harada.;Bianca Pourmussa.;Yogesh N V Reddy.;Michael D Jensen.;Rickey E Carter.;Ryan T Demmer.;Jeffrey M Testani.;Julio A Chirinos.;Barry A Borlaug.
来源: Circulation. 2024年150卷13期997-1009页
Systemic arterial compliance and venous capacitance are typically impaired in patients with heart failure with preserved ejection fraction (HFpEF), contributing to hemodynamic congestion with stress. Sodium-glucose cotransporter-2 inhibitors reduce hemodynamic congestion and improve clinical outcomes in patients with HFpEF, but the mechanisms remain unclear. This study tested the hypothesis that Dapagliflozin would improve systemic arterial compliance and venous capacitance during exercise in patients with HFpEF.
110. Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial.
作者: Catherine G Ireland.;Danielle S Burstein.;Sharlene M Day.;Anna Axelsson Raja.;Mark W Russell.;Kenneth G Zahka.;Alexandre Pereira.;Charles E Canter.;Richard G Bach.;Matthew T Wheeler.;Joseph W Rossano.;Anjali T Owens.;Henning Bundgaard.;Luisa Mestroni.;Matthew R G Taylor.;Amit R Patel.;Ivan Wilmot.;Jonathan H Soslow.;Jason R Becker.;Ilya Giverts.;E John Orav.;Brian Claggett.;Kimberly Y Lin.;Carolyn Y Ho.
来源: Circ Heart Fail. 2024年17卷8期e011663页
The health-related quality of life (HRQOL) and cardiopulmonary exercise testing (CPET) performance of individuals with subclinical and early stage hypertrophic cardiomyopathy (HCM) have not been systematically studied. Improved understanding will inform the natural history of HCM and factors influencing well-being.
111. Mapping-Guided Ablation for Persistent Atrial Fibrillation (MAP-AF): A Multicenter, Single-Blind, Randomized Controlled Trial.
作者: Yoshihide Takahashi.;Atsushi Kobori.;Kenichi Hiroshima.;Yuichiro Sakamoto.;Masaomi Kimura.;Osamu Inaba.;Kojiro Tanimoto.;Ryoichi Hanazawa.;Akihiro Hirakawa.;Masahiko Goya.;Tetsuo Sasano.
来源: Circ Arrhythm Electrophysiol. 2024年17卷8期e012829页
The clinical outcome of pulmonary vein isolation (PVI) for persistent atrial fibrillation (AF) is suboptimal. Mapping studies have demonstrated atrial sites outside of the pulmonary veins displaying focal activation patterns during AF. We sought to determine whether adding catheter ablation of focal activation sites to PVI improves clinical outcomes of catheter ablation for persistent AF.
112. Identifying the Mechanisms of a Peripherally Limited Exercise Phenotype in Patients With Heart Failure With Preserved Ejection Fraction.
作者: Rachel J Skow.;Satyam Sarma.;James P MacNamara.;Miles F Bartlett.;Denis J Wakeham.;Zachary T Martin.;Mitchel Samels.;Damsara Nandadeva.;Tiffany L Brazile.;Jimin Ren.;Qi Fu.;Tony G Babb.;Bryce N Balmain.;Michael D Nelson.;Linda S Hynan.;Benjamin D Levine.;Paul J Fadel.;Mark J Haykowsky.;Christopher M Hearon.
来源: Circ Heart Fail. 2024年17卷8期e011693页
We identified peripherally limited patients using cardiopulmonary exercise testing and measured skeletal muscle oxygen transport and utilization during invasive single leg exercise testing to identify the mechanisms of the peripheral limitation.
113. Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation.
作者: Julia Aulin.;Karl Sjölin.;Johan Lindbäck.;Alexander P Benz.;John W Eikelboom.;Ziad Hijazi.;Kim Kultima.;Jonas Oldgren.;Lars Wallentin.;Joachim Burman.; .
来源: Circulation. 2024年150卷14期1090-1100页
Biomarkers reflecting brain injury are not routinely used in risk assessment of stroke in atrial fibrillation (AF). Neurofilament light chain (NFL) is a novel biomarker released into blood after cerebral insults. We investigated the association between plasma concentrations of NFL, other biomarkers, and risk of stroke and death in patients with AF not receiving oral anticoagulation.
114. Multicenter Prospective Randomized Study Comparing the Incidence of Periprocedural Cerebral Embolisms Caused by Catheter Ablation of Atrial Fibrillation Between Cryoballoon and Radiofrequency Ablation (Embo-Abl Study).
作者: Koji Miyamoto.;Koshiro Kanaoka.;Yasutoshi Ohta.;Masue Yoh.;Hiroki Takahashi.;Rena Tonegawa-Kuji.;Yuichiro Miyazaki.;Akinori Wakamiya.;Nobuhiko Ueda.;Kenzaburo Nakajima.;Tsukasa Kamakura.;Mitsuru Wada.;Kohei Ishibashi.;Yuko Inoue-Yamada.;Satoshi Nagase.;Takeshi Aiba.;Hironobu Ichikawa.;Akihisa Narai.;Tomohiro Nakase.;Masatoshi Koga.;Tetsuya Fukuda.;Naoya Kataoka.;Masahiko Takagi.;Kengo Kusano.
来源: Circ Arrhythm Electrophysiol. 2024年17卷8期e012952页 115. One-Year Outcomes of Transseptal Mitral Valve-in-Valve in Intermediate Surgical Risk Patients.
作者: S Chris Malaisrie.;Mayra Guerrero.;Charles Davidson.;Mathew Williams.;Fábio Sândoli de Brito.;Alexandre Abizaid.;Pinak Shah.;Tsuyoshi Kaneko.;Karl Poon.;Justin Levisay.;Xiao Yu.;Philippe Pibarot.;Rebecca T Hahn.;Philipp Blanke.;Martin B Leon.;Michael J Mack.;Alan Zajarias.; .
来源: Circ Cardiovasc Interv. 2024年17卷8期e013782页
Transcatheter mitral valve-in-valve replacement offers a less-invasive alternative for high-risk patients with bioprosthetic valve failure. Limited experience exists in intermediate-risk patients. We aim to evaluate 1-year outcomes of the PARTNER 3 mitral valve-in-valve study.
116. Heart Failure Events After Long-term Continuous Screening for Atrial Fibrillation: Results From the Randomized LOOP Study.
作者: Lucas Yixi Xing.;Søren Højberg.;Derk W Kriegerg.;Claus Graff.;Morten S Olesen.;Jeff S Healey.;William F McIntyre.;Axel Brandes.;Lars Køber.;Ketil Jørgen Haugan.;Jesper Hastrup Svendsen.;Søren Zöga Diederichsen.
来源: Circ Arrhythm Electrophysiol. 2024年17卷8期e012764页
Mounting evidence indicates that even device-detected subclinical atrial fibrillation is associated with a higher risk of heart failure (HF). However, the potential impact of atrial fibrillation screening on HF remains unknown.
117. Distal Ventricular Pacing for Drug-Refractory Mid-Cavity Obstructive Hypertrophic Cardiomyopathy: A Randomized, Placebo-Controlled Trial of Personalized Pacing.
作者: James W Malcolmson.;Rebecca K Hughes.;Tim Husselbury.;Kamran Khan.;Annastazia E Learoyd.;Martin Lees.;Eleanor C Wicks.;Jamie Smith.;Alexander D Simms.;James C Moon.;Luis R Lopes.;Constantinos O'Mahony.;Neha Sekhri.;Perry M Elliott.;Steffen E Petersen.;Mehul B Dhinoja.;Saidi A Mohiddin.
来源: Circ Arrhythm Electrophysiol. 2024年17卷7期e012570页
Patients with refractory, symptomatic left ventricular (LV) mid-cavity obstructive (LVMCO) hypertrophic cardiomyopathy have few therapeutic options. Right ventricular pacing is associated with modest hemodynamic and symptomatic improvement, and LV pacing pilot data suggest therapeutic potential. We hypothesized that site-specific pacing would reduce LVMCO gradients and improve symptoms.
118. Equitable Care for Hypertension: Blood Pressure and Patient-Reported Outcomes of the RICH LIFE Cluster Randomized Trial.
作者: Lisa A Cooper.;Jill A Marsteller.;Kathryn A Carson.;Katherine B Dietz.;Romsai T Boonyasai.;Carmen Alvarez.;Deidra C Crews.;Cheryl R Dennison Himmelfarb.;Chidinma A Ibe.;Lisa Lubomski.;Edgar R Miller.;Nae-Yuh Wang.;Gideon D Avornu.;Deven Brown.;Debra Hickman.;Michelle Simmons.;Ariella Apfel Stein.;Hsin-Chieh Yeh.; .
来源: Circulation. 2024年150卷3期230-242页
Disparities in hypertension control are well documented but underaddressed.
119. REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNA-Related Dilated Cardiomyopathy.
作者: Pablo Garcia-Pavia.;Jose Fernando Rodriguez Palomares.;Gianfranco Sinagra.;Roberto Barriales-Villa.;Neal K Lakdawala.;Robert L Gottlieb.;Randal I Goldberg.;Perry Elliott.;Patrice Lee.;Huihua Li.;Franca S Angeli.;Daniel P Judge.;Calum A MacRae.; .
来源: Circ Heart Fail. 2024年17卷7期e011548页
LMNA (lamin A/C)-related dilated cardiomyopathy is a rare genetic cause of heart failure. In a phase 2 trial and long-term extension, the selective p38α MAPK (mitogen-activated protein kinase) inhibitor, ARRY-371797 (PF-07265803), was associated with an improved 6-minute walk test at 12 weeks, which was preserved over 144 weeks.
120. Atrioventricular Synchrony Delivered by a Dual-Chamber Leadless Pacemaker System.
作者: James E Ip.;Mayer Rashtian.;Derek V Exner.;Vivek Y Reddy.;Rahul Doshi.;Nima Badie.;Jordan R Nevo.;Aditya Goil.;Pascal Defaye.;Robert Canby.;Maria Grazia Bongiorni.;Morio Shoda.;Gerhard Hindricks.;Reinoud E Knops.
来源: Circulation. 2024年150卷6期439-450页
A dual-chamber leadless pacemaker system has been designed for atrioventricular synchronous pacing using wireless, beat-to-beat, implant-to-implant (i2i) communication between distinct atrial and ventricular leadless pacemakers. The atrioventricular synchrony achieved across various ambulatory scenarios has yet to be systematically evaluated.
|